Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 38K
5: R1 Cover HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- podd-20220914_htm XML 21K
7: EXCEL IDEA Workbook of Financial Reports XLSX 8K
3: EX-101.LAB XBRL Labels -- podd-20220914_lab XML 67K
4: EX-101.PRE XBRL Presentations -- podd-20220914_pre XML 33K
2: EX-101.SCH XBRL Schema -- podd-20220914 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 16K
10: ZIP XBRL Zipped Folder -- 0001145197-22-000049-xbrl Zip 16K
(Address
of Principal Executive Offices, including Zip Code)
Registrant’s telephone number, including area code:
i(978)
i600-7000
Not
Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
i☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act
☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
iCommon Stock, $0.001 Par Value Per Share
iPODD
iThe
NASDAQ Stock Market, LLC
Item 7.01
Regulation FD Disclosure
On August 4, 2022, Insulet Corporation (the “Company”) held a conference call to discuss its financial results for the second quarter ended June
30, 2022.During the call, the Company advised that it expected gross margin for 2022 to be in the range of 65% to 66%.
On September 14, 2022, the Company participated in the Baird 2022 Global Healthcare Conference.The Company recently became aware that, during the question-and-answer portion of the Company’s presentation, a Company executive misspoke and referred to
gross margin guidance in the 64% to 65% range for 2022.This reference was an inadvertent error and was not intended to update the previously issued guidance.
In issuing this 8-K, the Company is not affirming or updating guidance but merely correcting a misstatement. The Company disclaims any intention or obligation to update or revise its prior guidance, whether as a result of new information, future events or otherwise.
The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability
of that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized.